Titan Pharmaceuticals Financials

TTNP Stock  USD 4.19  0.54  14.79%   
Based on the key indicators related to Titan Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Titan Pharmaceuticals may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Titan Pharmaceuticals' Short and Long Term Debt is relatively stable compared to the past year. Key indicators impacting Titan Pharmaceuticals' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio8.276.0518
Significantly Up
Slightly volatile
The essential information of the day-to-day investment outlook for Titan Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Titan Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Titan Pharmaceuticals.

Net Income

(4.94 Million)

  

Titan Pharmaceuticals Stock Summary

Titan Pharmaceuticals competes with Salarius Pharmaceuticals, SAB Biotherapeutics, GeoVax Labs, Senti Biosciences, and Cadrenal Therapeutics,. Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. The company was incorporated in 1992 and is based in South San Francisco, California. Titan Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS8883146065
CUSIP888314309 888314606 888314507 888314705 888314101 888314200
LocationCalifornia; U.S.A
Business Address400 Oyster Point
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.titanpharm.com
Phone650 244 4990
CurrencyUSD - US Dollar

Titan Pharmaceuticals Key Financial Ratios

Titan Pharmaceuticals Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets8.1M8.0M4.1M8.1M2.9M2.8M
Other Current Liab2.3M1.4M1.5M519K281K267.0K
Net Debt(4.6M)(5.7M)(2.8M)(6.2M)(2.8M)(3.0M)
Retained Earnings(367.3M)(376.1M)(386.3M)(391.8M)(396.5M)(376.7M)
Accounts Payable1.3M795K695K348K202K191.9K
Cash5.4M6.0M2.9M6.8M2.8M2.7M
Net Receivables884K112K36K1.0M1.2M1.6M
Total Liab4.6M2.9M2.7M1.4M483K458.9K
Total Current Assets7.3M7.2M3.6M8.0M2.9M2.8M
Short Term Debt627K224K244K565K508.5K483.1K
Other Current Assets703K787K524K199K92K87.4K
Common Stock7K10K15K1K900.0855.0
Net Tangible Assets6.8M1.4M3.5M5.1M4.6M4.7M
Net Invested Capital4.2M5.1M1.4M7.1M6.4M4.8M

Titan Pharmaceuticals Key Income Statement Accounts

The reason investors look at the income statement is to determine what Titan Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
202020212022202320242025 (projected)
Interest Expense967K769K1K29K33.4K31.7K
Total Revenue4.8M1.5M60K184K211.6K201.0K
Gross Profit4.4M1.3M(136K)72K64.8K61.6K
Operating Income(7.4M)(9.4M)(10.2M)(7.3M)(4.6M)(4.8M)
Ebit(7.4M)(9.4M)(10.2M)(7.3M)(8.4M)(8.8M)
Ebitda(7.1M)(9.1M)(10.0M)(7.2M)(4.6M)(4.8M)
Cost Of Revenue472K199K196K112K100.8K95.8K
Income Before Tax(7.4M)(8.8M)(10.2M)(5.6M)(4.7M)(4.9M)
Net Income(20.7M)(8.1M)(10.2M)(5.6M)(4.7M)(4.9M)
Income Tax Expense13.3M(662K)(29K)(55.9K)(64.3K)(67.5K)
Research Development5.9M5.7M4.8M1.9M1.7M1.6M
Net Interest Income(769K)1K53K45K51.8K54.3K

Titan Pharmaceuticals Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash190K919K(3.2M)3.6M(3.9M)(3.7M)
Free Cash Flow(17.7M)(7.9M)(8.2M)(7.1M)(3.9M)(4.1M)
Depreciation292K221K196K112K5K4.8K
Other Non Cash Items482K(5K)452K(1.7M)821K946.7K
Net Income(18.2M)(8.8M)(10.2M)(5.6M)(4.7M)(4.9M)
End Period Cash Flow5.4M6.3M3.1M6.8M2.8M2.7M
Change To Inventory287K35K187K354K407.1K427.5K
Change To Netincome620K(192K)(271K)875K787.5K557.4K
Investments(540K)(23K)(5K)228K262.2K275.3K

Titan Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Titan Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Titan Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Titan Pharmaceuticals competition to find correlations between indicators driving Titan Pharmaceuticals's intrinsic value. More Info.
Titan Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Titan Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Titan Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Titan Pharmaceuticals Systematic Risk

Titan Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Titan Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Titan Pharmaceuticals correlated with the market. If Beta is less than 0 Titan Pharmaceuticals generally moves in the opposite direction as compared to the market. If Titan Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Titan Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Titan Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Titan Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Titan Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Titan Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Titan Pharmaceuticals growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0222

At this time, Titan Pharmaceuticals' Price Earnings To Growth Ratio is relatively stable compared to the past year.

Titan Pharmaceuticals March 23, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Titan Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Titan Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Titan Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Titan Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Titan Pharmaceuticals's daily price indicators and compare them against related drivers.

Additional Tools for Titan Stock Analysis

When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.